Fox Chase Cancer Center

It is the highest classification awarded by the National Cancer Institute, granted only to institutions that demonstrate deep expertise across laboratory research, clinical trials, and population science. Fox Chase has held this designation continuously since 1974. The status requires re-competition every five years through a rigorous external peer-review process that evaluates scientific programs, shared resources, and community outreach.

Fox Chase joined the Temple University Health System in 2012. The center retains its own campus, faculty, and NCI designation while serving as Temple's principal academic oncology arm. Patients can access Temple Health's broader clinical network, but Fox Chase's research enterprise operates under its own Cancer Center Support Grant and governance structure.

The center maintains four NCI-evaluated scientific programs: Cancer Prevention and Control, Molecular Therapeutics, Immune Cell Regulation and Targeting, and an additional program in basic cellular mechanisms. Clinical research emphasizes prostate, breast, and lung cancers, with extensive early-phase trial activity. The center also houses a nationally recognized population-science program focused on cancer risk and health disparities.

Fox Chase does not publicly report a separate institutional endowment in the manner of a university or private foundation. Research operations are funded through NCI grants, pharmaceutical partnerships, and philanthropic giving. The Fox Chase Cancer Center Foundation, a 501(c)(3), receives and stewards charitable gifts, including a $50 million donation announced in 2023.

Fox Chase is part of the Temple University Health System but is not a member of a national consortium like the National Comprehensive Cancer Network. It collaborates with other cancer centers on specific trials and research projects, and its faculty hold academic appointments through the Lewis Katz School of Medicine at Temple University.